Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

WATERTOWN, Mass., May 11 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.  The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients.

"Patients with Alzheimer's disease have a number of symptomatic therapies available to them. However, the effects of the available medications are modest. Even if significant progress is made in slowing disease progression, more effective therapies that sustainably improve the cognition of the patients are clearly needed," said Kees Been, EnVivo president and CEO. "There is growing consensus that alpha-7 nicotinic agonists can potentially improve the cognitive function in Alzheimer's disease patients as evidenced by the number of large pharmaceutical companies advancing similar drugs through development. The potential upside for patients is considerable and we look forward to completing our Alzheimer's disease study by the middle of next year."

The Phase IIb study will enroll mild to moderate Alzheimer's disease patients who will be randomized to three separate doses of EVP-6124 or placebo over six months. Efficacy will primarily be determined by the ADAS-Cog scale, a commonly used and accepted measure of cognition in patients with Alzheimer's disease. Secondary assessments will include other cognitive and clinical measures. EVP-6124 also is being tested in patients with schizophrenia in a separate Phase IIb study that started in late 2009
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015 The global genotyping ... 22.3% during the forecast period of 2015 to 2020 ... being used in drug discovery and development process and ... growth. In addition to this,heavy investments by key manufacturers ... are also propelling market growth. Browse 113 market data ...
(Date:5/20/2015)... May 20, 2015  Marc Tessier-Lavigne, president of ... of $100 million from The Marie-Josée and Henry ... laboratory building that will be the centerpiece of ... and Henry R. Kravis Research Building, two stories ... spanning approximately three city blocks following the shoreline ...
(Date:5/20/2015)...  Resolution Bioscience announced today the successful results from ... , a blood-based liquid biopsy for an ALK-gene fusion driver ... most common form of this cancer. Researchers or clinicians ... personalized therapies and direct them into clinical trials with ... Health, the CLIA authority in Washington State ...
(Date:5/20/2015)... France, Cambridge, MA (PRWEB) May 20, 2015 ... high quality transporter assay services for Drug-Drug Interactions ... and Rhenovia Pharma, a world leader in assessing ... Translational Quantitative Systems Pharmacology supported by biosimulation, announced ... , The agreement allows both companies to expand ...
Breaking Biology Technology:Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... TOWN, South Africa, Oct. 11, Iomai Corporation (Nasdaq: ... Glenn, M.D., presented an,overview of the clinical data for ... a vaccine could have on,global health at the Keystone ... Town, South Africa. Last month, Dr. Glenn presented ...
... quarter of 2007 increased 25 percent compared to the third quarter ... ... (NYSE: CRY ),a biomaterials, medical device and tissue processing company, ... 2007 were approximately $21.9 million compared to $20.0 million in the,third ...
... Genome Sciences (UK),Ltd "OGeS" announces today that it ... the appointment of Sir Walter Bodmer, currently,Head of ... of Molecular Medicine at the University of Oxford, ... changes which,lead to the development of colorectal cancer. ...
Cached Biology Technology:Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 2Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 3Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 3CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 5Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board 2Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board 3
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... Tech in the United States have determined the structure ... xanthurenic acid (XA) in Anopheles gambiae, the malaria carrying ... reproduction of the malaria parasite (Plasmodium falciparum) in A. ... be an avenue for development of drugs and insecticides ...
... show that regular use of popular prescription pain relievers may ... percent and may offer similar benefit in the prevention of ... were released today at the annual meeting of the American ... believe this is the first study to show that selective ...
... Have you ever tried to do the limbo? For ants ... Zurich have discovered that ants are able to learn how ... they can successfully crawl under it without slowing down. Tobias ... Annual Meeting for the Society for Experimental Biology on Tuesday ...
Cached Biology News:Oxidation defense in mosquitoes benefits malaria parasite 2COX-2 inhibitors significantly reduce risk of cancer 2
... GeneMaths XT is undoubtedly the most complete ... advanced concept of layers and subsets makes ... layers for different data outputs, for example ... etc., as well as different subsets of ...
...
...
... for Mac OS X provides the most ... protein sequence analysis and molecular biology data ... 1). With Vector NTI Suite you can ... publicize diverse types of molecular biology data ...
Biology Products: